Although the combination of LU-102 and Btz or Cfz is an attractive treatment strategy, monotherapy with LU-102 showed lower cytotoxicity in Btz-resistant MM cells, suggesting that selective elimination of T-L activity alone is insufficient to have a meaningful anti-tumor effect on Btz-resistant MM cells [28]. Here, BCAM is linked to Miyoshi myopathy.